carmellrx.com (CTCX) - Market Value to Book Value Ratio

Carmell Corp. (CTCX) - corporate logo

Carmell Corporation (CTCX) is pursuing expansion by scaling regenerative biomaterials. In the price-to-book history illustrated by this GURU.Markets chart, the value -2.81 represents the current metric. Unique plasma products for surgery provide stability, yet business success relies on effective commercialization and strict operational expense control supported by sufficient reserves.

Carmell Therapeutics (CTCX) - Market Value to Book Value from 02/21/2024 to 03/10/2025
Manufactured product of Carmell Corp

Carmell Corporation (CTCX) effectively combines long-term biomedical developments with operational revenue from aesthetic cosmetics. The market-to-book ratio measures the investor premium over the issuer's net assets. This coefficient reflects market confidence in the business's ability to offset cost inflation. A high asset valuation facilitates access to capital despite regulatory risks. The history of the price-to-book ratio clearly demonstrates the dynamics of this balance.

Competitor analysis

ASND (Ascendis Pharma A/S) - Market Cap to Net Assets Ratio|Capitalization to Book Value Ratio MDGL|Market Value to Book Value Ratio Corcept Therapeutics Incorporated|Rhythm Pharma - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio AKRO|MTSR (Metsera Therapeutics) - Market Value to Book Value|Market Capitalization to Book Value Ratio MLTX (MoonLake Immunotherapeutics)|Market Capitalization to Book Value Ratio crinetics.com CRNX|NAMS - Market Value to Book Value Ratio|Market Value to Book Value SLNO (Soleno Therapeutics Inc)|Amicus Pharma (FOLD) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio 89bio Pharma|AGIO (Agios Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio structuretx.com|Market Cap to Net Assets Ratio MDXG (MiMedx)|RZLT (Rezolute Inc) - Market Value to Book Value|Market Value to Book Value Ratio Lexicon Pharma LXRX|MBX - Market Cap to Net Assets Ratio|Altimmune, Inc. - Market Capitalization to Book Value Ratio|Market-to-Book Ratio aardvarktherapeutics.com|SGMT (Sagimet Biosciences Inc.) - Market Cap to Net Assets Ratio|BIOA: Market Cap to Book Value Multiple|BMEA (Biomea) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Quince|Market Capitalization to Book Value Ratio GUTS|Market Value to Book Value Ratio VTVT (vtvtherapeutics.com)|Market Value to Book Value Ratio Agape ATP ATPC|Pluristem Therapeutics (PLUR) - Market-to-Book Ratio|SYBX - Market Value to Book Value Ratio|LPCN: Market Value to Book Value Ratio|MTNB: Market Capitalization to Book Value Ratio|SPRB - Market Capitalization to Book Value|Market Value to Book Value Ratio Galecto|Lumos Pharma Inc (LUMO) - Market Capitalization to Book Value|Market Value to Book Value Ratio Organovo Holdings Inc (ONVO)|Market Cap to Net Assets Ratio Radius Pharmaceuticals RDUS